Long-term safety and efficacy of ziv-aflibercept in retinal diseases [PDF]
British Journal of Ophthalmology, 2017 To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept.Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three ...
Ahmad M Mansour +5 more
openaire +3 more sources
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer [PDF]
BMC Cancer, 2019 Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose ...
John H. Strickler +19 more
doaj +2 more sources
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy [PDF]
Indian Journal of Ophthalmology, 2019 Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV).
Sumit Randhir Singh +3 more
doaj +2 more sources
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. [PDF]
Oncologist, 2018 Abstract Lessons Learned The combination of the antiangiogenic agent ziv-aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested.
Meehan R +8 more
europepmc +5 more sources
Safety of 5914 intravitreal ziv-aflibercept injections [PDF]
British Journal of Ophthalmology, 2018 PurposeTo analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.MethodsThis was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated.
Sumit Randhir Singh +21 more
openaire +3 more sources
Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy [PDF]
British Journal of Ophthalmology, 2018 AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour +4 more
openaire +3 more sources
Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study [PDF]
Clinical Ophthalmology, 2018 Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland ...
Doepfner JM +4 more
doaj +2 more sources
INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA
Retina, 2016 Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs.
Gabriel Costa de, Andrade +5 more
openaire +3 more sources
Taiwan Journal of Ophthalmology, 2020 PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD).
Sumit Randhir Singh +7 more
doaj +2 more sources
Two-year outcomes of intravitreal ziv-aflibercept
British Journal of Ophthalmology, 2018 Aim To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. Methods Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at ...
Ahmad M Mansour +7 more
openaire +3 more sources